Comparison tool

Exenatide vs Dulaglutide side-by-side

Stack up to four peptides by evidence status, mechanisms, study dosing, side effects, and references.

Selected (2/4)

ExenatideDulaglutide

Share this peptide comparison

Property	Exenatide	Dulaglutide
Category	Weight Loss	Weight Loss
Also known as	Byetta, Bydureon, Exendin-4	Trulicity
FDA approved	Yes	Yes
Clinical status	FDA approved for type 2 diabetes in adults and pediatric patients ages 10-17; source also notes Byetta and Bydureon BCise were discontinued Oct 2024 and that an Amneal generic is available. Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved	FDA Approved - Type 2 diabetes Pre Preclinical I Phase I II Phase II III Phase III IV Phase IV FDA FDA approved
What to expect	Diabetes management, weight loss, glucose control	Blood sugar control, weight management, diabetes
How it works	Exenatide is reported to act at the GLP-1 receptor. The source links that receptor activity with glucose-dependent insulin secretion, reduced excess glucagon, delayed gastric emptying, and satiety. It also distinguishes Exenatide from native GLP-1 by noting resistance to DPP-4 degradation: native GLP-1 is described as lasting about two minutes, while Exenatide is reported to circulate with an approximately 2.4-hour half-life. For the once-weekly Bydureon formulation, the source describes slow release from polymer microspheres over days.	Dulaglutide is presented as a GLP-1 receptor agonist. The supplied mechanism states that GLP-1 receptor activation supports insulin release when glucose is present, reduces glucagon, and slows gastric emptying. The molecule is described as a modified GLP-1 peptide attached to a human antibody Fc fragment; the source says this larger Fc-linked design reduces rapid renal clearance and helps protect the peptide from DPP-4 degradation. Appetite and modest weight-related effects are attributed in the source to GLP-1 signaling in hunger-regulating brain regions.
Typical dosing	5-10 mcg twice daily or 2 mg weekly · Twice daily (IR) or once weekly (ER) · Subcutaneous injection	1.5-4.5 mg weekly · Once weekly
Research dosing	5-10 mcg twice daily (Byetta) · Long-term / chronic use · Subcutaneous injection	0.75mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly
Typical duration	Long-term / chronic use	Long-term / chronic use
Administration	Subcutaneous injection	Subcutaneous injection weekly
Timing	Before bed or morning, fasted Take on an empty stomach	Before bed or morning (fasted) Take on empty stomach
Evidence level	FDA Approved	FDA Approved
Possible side effects	Nausea (Listed as common; research summary says nausea was the most common side effect and often decreased over time.) Vomiting (Reported in the source side-effect list.) Diarrhea (Reported in the source side-effect list.) +5 more Dizziness (Reported in the source side-effect list.) Hypoglycemia (Reported in the source side-effect list.) Injection site reactions (Reported in the source side-effect list.) Pancreatitis (Source lists pancreatitis with a boxed-warning note and also reports rare post-marketing acute pancreatitis cases.) Acute kidney injury (Reported in the source side-effect list; the source also states Exenatide is not recommended in severe kidney impairment.)	Nausea (Listed by source; gastrointestinal effects are described as typical downsides.) Diarrhea (Listed by source; gastrointestinal effects are described as typical downsides.) Vomiting (Listed by source.) +7 more Abdominal pain (Listed by source.) Injection site reactions (Listed by source.) Hypoglycemia (with insulin/sulfonylureas) (Source qualifies this risk as occurring with insulin or sulfonylureas.) Pancreatitis (Listed by source.) Gallbladder problems (Listed by source.) BOXED WARNING: Thyroid C-cell tumors (Source states this boxed warning is based on rodent data.) FDA approved (Trulicity) (Listed in the source side-effects array, but this is a regulatory/identity note rather than an adverse effect.)
Research summary	The source characterizes Exenatide as an established FDA-approved drug with substantial human clinical experience rather than an experimental compound. It cites peer-reviewed literature, including a 2012 Regulatory Peptides review, for its path from Gila monster venom research to an approved antidiabetic medication. In type 2 diabetes trials, the source reports lower HbA1c and modest weight loss, with nausea identified as the most common side effect and often diminishing over time. It also states that the EXSCEL cardiovascular outcomes trial found once-weekly Exenatide cardiovascularly safe but did not demonstrate a statistically significant reduction in cardiovascular events. Source cautions include rare post-marketing acute pancreatitis reports and lack of recommendation in severe kidney impairment; it also frames Exenatide as an older GLP-1 class option compared with newer agents such as semaglutide and dulaglutide.	The source characterizes Dulaglutide as supported by human clinical evidence rather than only animal work. It cites the AWARD program for glucose-lowering evidence across multiple type 2 diabetes contexts. It also highlights the 2019 Lancet REWIND trial, which followed more than 9,900 participants for a median period exceeding five years; about 69% reportedly had no previous cardiovascular disease. In that trial summary, major cardiovascular events were lower with dulaglutide than placebo, reported as 12.0% versus 13.4% with a hazard ratio of 0.88. The source notes gastrointestinal tolerability issues such as nausea and diarrhea and states that the class carries a boxed warning about thyroid C-cell tumors based on rodent findings.
References	PubMed Wikipedia +1 more ScienceDirect	Source Source +1 more Source
Full profile	View Details	View Details

Save this comparison

Keep this research set handy with a free PeptiGuide account.

Save this comparison - free account

Track your peptide journey

Turn research into a private protocol log when you are ready.

Track your peptide journey

Educational use only. This information is aggregated from public research and community reports. It is not medical advice, and dosing details are descriptive, not recommendations. Always consult a qualified healthcare professional.

Property

Exenatide

Dulaglutide

Category

Weight Loss

Also known as

Byetta, Bydureon, Exendin-4

Trulicity

FDA approved

Yes

Clinical status

FDA approved for type 2 diabetes in adults and pediatric patients ages 10-17; source also notes Byetta and Bydureon BCise were discontinued Oct 2024 and that an Amneal generic is available.

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

FDA Approved - Type 2 diabetes

Pre
Preclinical
I
Phase I
II
Phase II
III
Phase III
IV
Phase IV
FDA
FDA approved

What to expect

Diabetes management, weight loss, glucose control

Blood sugar control, weight management, diabetes

How it works

Exenatide is reported to act at the GLP-1 receptor. The source links that receptor activity with glucose-dependent insulin secretion, reduced excess glucagon, delayed gastric emptying, and satiety. It also distinguishes Exenatide from native GLP-1 by noting resistance to DPP-4 degradation: native GLP-1 is described as lasting about two minutes, while Exenatide is reported to circulate with an approximately 2.4-hour half-life. For the once-weekly Bydureon formulation, the source describes slow release from polymer microspheres over days.

Dulaglutide is presented as a GLP-1 receptor agonist. The supplied mechanism states that GLP-1 receptor activation supports insulin release when glucose is present, reduces glucagon, and slows gastric emptying. The molecule is described as a modified GLP-1 peptide attached to a human antibody Fc fragment; the source says this larger Fc-linked design reduces rapid renal clearance and helps protect the peptide from DPP-4 degradation. Appetite and modest weight-related effects are attributed in the source to GLP-1 signaling in hunger-regulating brain regions.

Typical dosing

5-10 mcg twice daily or 2 mg weekly · Twice daily (IR) or once weekly (ER) · Subcutaneous injection

1.5-4.5 mg weekly · Once weekly

Research dosing

5-10 mcg twice daily (Byetta) · Long-term / chronic use · Subcutaneous injection

0.75mg weekly (starting) · Long-term / chronic use · Subcutaneous injection weekly

Typical duration

Long-term / chronic use

Administration

Subcutaneous injection

Subcutaneous injection weekly

Timing

Before bed or morning, fasted

Take on an empty stomach

Before bed or morning (fasted)

Take on empty stomach

Evidence level

FDA Approved

Possible side effects

Nausea (Listed as common; research summary says nausea was the most common side effect and often decreased over time.)
Vomiting (Reported in the source side-effect list.)
Diarrhea (Reported in the source side-effect list.)

+5 more

Dizziness (Reported in the source side-effect list.)
Hypoglycemia (Reported in the source side-effect list.)
Injection site reactions (Reported in the source side-effect list.)
Pancreatitis (Source lists pancreatitis with a boxed-warning note and also reports rare post-marketing acute pancreatitis cases.)
Acute kidney injury (Reported in the source side-effect list; the source also states Exenatide is not recommended in severe kidney impairment.)

Nausea (Listed by source; gastrointestinal effects are described as typical downsides.)
Diarrhea (Listed by source; gastrointestinal effects are described as typical downsides.)
Vomiting (Listed by source.)

+7 more

Abdominal pain (Listed by source.)
Injection site reactions (Listed by source.)
Hypoglycemia (with insulin/sulfonylureas) (Source qualifies this risk as occurring with insulin or sulfonylureas.)
Pancreatitis (Listed by source.)
Gallbladder problems (Listed by source.)
BOXED WARNING: Thyroid C-cell tumors (Source states this boxed warning is based on rodent data.)
FDA approved (Trulicity) (Listed in the source side-effects array, but this is a regulatory/identity note rather than an adverse effect.)

Research summary

The source characterizes Exenatide as an established FDA-approved drug with substantial human clinical experience rather than an experimental compound. It cites peer-reviewed literature, including a 2012 Regulatory Peptides review, for its path from Gila monster venom research to an approved antidiabetic medication. In type 2 diabetes trials, the source reports lower HbA1c and modest weight loss, with nausea identified as the most common side effect and often diminishing over time. It also states that the EXSCEL cardiovascular outcomes trial found once-weekly Exenatide cardiovascularly safe but did not demonstrate a statistically significant reduction in cardiovascular events. Source cautions include rare post-marketing acute pancreatitis reports and lack of recommendation in severe kidney impairment; it also frames Exenatide as an older GLP-1 class option compared with newer agents such as semaglutide and dulaglutide.

The source characterizes Dulaglutide as supported by human clinical evidence rather than only animal work. It cites the AWARD program for glucose-lowering evidence across multiple type 2 diabetes contexts. It also highlights the 2019 Lancet REWIND trial, which followed more than 9,900 participants for a median period exceeding five years; about 69% reportedly had no previous cardiovascular disease. In that trial summary, major cardiovascular events were lower with dulaglutide than placebo, reported as 12.0% versus 13.4% with a hazard ratio of 0.88. The source notes gastrointestinal tolerability issues such as nausea and diarrhea and states that the class carries a boxed warning about thyroid C-cell tumors based on rodent findings.

References

+1 more

+1 more

Full profile